Content for healthcare professionals only

View all Platforms Cardiology

Topics Content Type Videos Articles Journals Broadcasts Education Podcasts News Journals AER CFR ECR ICR3 JAPSC USC Faculty Events Upcoming Events Radcliffe Events All Events Resource Hubs Empagliflozin in the Treatment of Chronic Heart Failure Pulmonary Embolism Pulsed Field Ablation

Radcliffe Platforms

Radcliffe Group Cardiology Vascular CVRM Medical Education

Content for healthcare professionals only

Content Type

Events

Resource Hubs

DOACs: 60 Second Insights

Published: 18 June 2018

Views:
669
Likes:
7

Views:
669
Likes:
7
Share:

Now Playing
Part 1 | Session 4 of 11
What are the most important anticoagulation clinical trials?
Christopher P Cannon

Up Next
45s

Part 1 | Session 5 Do you have a DOAC of choice?
Moussa Mansour
41s

Part 1 | Session 6 How important are reversal agents? - Christoper Cannon
Christopher P Cannon
42s

Part 1 | Session 7 How important are reversal agents? - Moussa Mansour
Moussa Mansour
36s

Part 1 | Session 8 Are you once-daily or twice-daily? - Christopher Cannon
Christopher P Cannon
33s

Part 1 | Session 9 Are you once-daily or twice-daily? - Moussa Mansour
Moussa Mansour
38s

Part 1 | Session 10 Is RCT or real-world data more important to you? - Christopher Cannon
Christopher P Cannon
1m 3s

Part 1 | Session 11 Is RCT or real-world data more important to you? - Moussa Mansour
Moussa Mansour

50s

Part 1 | Session 1 What are the challeges of DOACs and are alternatives needed? Christopher P Cannon

46s

Part 1 | Session 2 What factors influence your choice of DOAC? Christopher P Cannon

46s

Part 1 | Session 3 Do you have a DOAC you prescribe more frequently? Christopher P Cannon

Average (ratings)

No ratings

Your rating

Overview

Christopher Cannon and Moussa Mansour share their thoughts on DOACs in a series of 60-second interviews

More from this programme

Part 1

DOACs

11 sessions
What are the challeges of DOACs and are alternatives needed?	Watch now
What factors influence your choice of DOAC?	Watch now
Do you have a DOAC you prescribe more frequently?	Watch now
What are the most important anticoagulation clinical trials?	Watch now
Do you have a DOAC of choice?	Watch now
How important are reversal agents? - Christoper Cannon	Watch now
How important are reversal agents? - Moussa Mansour	Watch now
Are you once-daily or twice-daily? - Christopher Cannon	Watch now
Are you once-daily or twice-daily? - Moussa Mansour	Watch now
Is RCT or real-world data more important to you? - Christopher Cannon	Watch now
Is RCT or real-world data more important to you? - Moussa Mansour	Watch now

Faculty Biographies

Christopher P Cannon

Christopher P Cannon

Professor

Dr Christopher Cannon is a Professor of Medicine at Harvard Medical School, and Senior Physician in the Preventive Cardiology section of the Cardiovascular Division at Brigham and Women’s Hospital.

He earned his MD from Columbia University College of Physicians and Surgeons in New York and did internal medicine residency at Columbia Presbyterian Medical Center, and cardiovascular fellowship at Brigham and Women’s Hospital.

Dr Cannon has published over 1000 original articles, reviews or book chapters in the field of acute coronary syndromes and prevention and has authored or edited 18 books. He has received numerous awards, including leadership awards from the American College of Cardiology, American Heart Association and National Lipid Association.

He has been principal investigator of more than 20 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, IMPROVE IT, RE-DUAL PCI and VERTIS CV trials.

Dr Cannon is on the…

View full profile